Marshall Wace LLP Has $90.75 Million Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Marshall Wace LLP cut its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 4.9% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The firm owned 127,400 shares of the biopharmaceutical company’s stock after selling 6,604 shares during the period. Marshall Wace LLP’s holdings in Regeneron Pharmaceuticals were worth $90,751,000 at the end of the most recent reporting period.

Other large investors have also made changes to their positions in the company. Virtu Financial LLC bought a new stake in shares of Regeneron Pharmaceuticals in the third quarter worth about $6,364,000. Morse Asset Management Inc raised its holdings in Regeneron Pharmaceuticals by 0.9% during the 3rd quarter. Morse Asset Management Inc now owns 4,807 shares of the biopharmaceutical company’s stock worth $5,053,000 after buying an additional 43 shares during the period. Anchor Investment Management LLC lifted its stake in Regeneron Pharmaceuticals by 212.0% in the third quarter. Anchor Investment Management LLC now owns 858 shares of the biopharmaceutical company’s stock valued at $902,000 after buying an additional 583 shares in the last quarter. Sculati Wealth Management LLC increased its position in shares of Regeneron Pharmaceuticals by 1.9% during the third quarter. Sculati Wealth Management LLC now owns 2,047 shares of the biopharmaceutical company’s stock worth $1,970,000 after acquiring an additional 38 shares in the last quarter. Finally, Pine Valley Investments Ltd Liability Co lifted its position in Regeneron Pharmaceuticals by 19.0% in the 3rd quarter. Pine Valley Investments Ltd Liability Co now owns 5,303 shares of the biopharmaceutical company’s stock valued at $5,575,000 after acquiring an additional 848 shares in the last quarter. Institutional investors own 83.31% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts have issued reports on the company. The Goldman Sachs Group lowered their target price on Regeneron Pharmaceuticals from $1,019.00 to $917.00 and set a “buy” rating for the company in a report on Monday. TD Cowen reduced their price target on Regeneron Pharmaceuticals from $1,230.00 to $1,030.00 and set a “buy” rating for the company in a research report on Tuesday, February 4th. JPMorgan Chase & Co. lowered their price objective on shares of Regeneron Pharmaceuticals from $1,100.00 to $1,000.00 and set an “overweight” rating on the stock in a report on Monday, March 31st. Sanford C. Bernstein decreased their target price on shares of Regeneron Pharmaceuticals from $1,110.00 to $1,070.00 and set an “outperform” rating for the company in a research report on Tuesday, January 7th. Finally, Piper Sandler reduced their price objective on shares of Regeneron Pharmaceuticals from $1,195.00 to $1,013.00 and set an “overweight” rating for the company in a research note on Monday, January 27th. One research analyst has rated the stock with a sell rating, six have issued a hold rating, eighteen have assigned a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat.com, Regeneron Pharmaceuticals currently has a consensus rating of “Moderate Buy” and a consensus target price of $964.88.

Regeneron Pharmaceuticals Price Performance

Shares of NASDAQ REGN opened at $549.28 on Thursday. The firm has a market cap of $60.05 billion, a P/E ratio of 14.35, a price-to-earnings-growth ratio of 2.34 and a beta of 0.44. The business’s 50 day moving average is $650.53 and its 200-day moving average is $747.23. The company has a current ratio of 4.73, a quick ratio of 3.95 and a debt-to-equity ratio of 0.09. Regeneron Pharmaceuticals, Inc. has a 1-year low of $525.99 and a 1-year high of $1,211.20.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $12.07 earnings per share for the quarter, topping analysts’ consensus estimates of $11.21 by $0.86. Regeneron Pharmaceuticals had a return on equity of 16.32% and a net margin of 31.07%. The company had revenue of $3.79 billion during the quarter, compared to the consensus estimate of $3.76 billion. During the same quarter last year, the firm earned $11.86 earnings per share. The company’s revenue was up 10.3% on a year-over-year basis. Equities research analysts predict that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current year.

Regeneron Pharmaceuticals Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Thursday, March 20th. Shareholders of record on Thursday, February 20th were issued a $0.88 dividend. This represents a $3.52 dividend on an annualized basis and a yield of 0.64%. The ex-dividend date of this dividend was Thursday, February 20th. Regeneron Pharmaceuticals’s dividend payout ratio is currently 2.30%.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.